NasdaqGS:COLLPharmaceuticals
How Strong Q1 Earnings and Executive Departures At Collegium Pharmaceutical (COLL) Have Changed Its Investment Story
Collegium Pharmaceutical recently reported first-quarter 2026 net income of US$14.5 million, a sharp increase from US$2.42 million a year earlier, reaffirmed its full-year product revenue guidance of US$805 million to US$825 million, and disclosed upcoming departures of its Chief Commercial Officer and Chief Medical Officer, both classified as terminations without cause.
The combination of stronger earnings driven by JORNAY PM and pain products, steady full-year guidance, and impending...